CNO Financial Group (CNO) Q2 2026 earnings review
Record Sales Streak Extends as Earnings Accelerate
CNO Financial delivered a blowout second quarter, highlighted by a 45% year-over-year surge in operating EPS to $1.26 and its 16th consecutive quarter of sales growth. Supported by strong net investment income and record Worksite NAP, management confidently raised its full-year 2026 operating EPS guidance by 8% at the midpoint. While underlying momentum is robust and capital return remains steady, total insurance policy benefits grew significantly faster than policy income in Q2, suggesting some underlying margin pressures that require monitoring.
🐂 Bull Case
16 consecutive quarters of sales growth across the enterprise validates CNO's competitive moat in the middle-income demographic. The Worksite division, in particular, accelerated with 29% YoY NAP growth.
General account net investment income increased 9% YoY, driven by over three years of new money rates exceeding 6%. This structural tailwind continues to drop straight to the bottom line.
🐻 Bear Case
Insurance policy benefits spiked nearly 13% YoY compared to just 4.5% growth in insurance policy income. If Med Supp morbidity issues persist, they could compress currently healthy product margins.
Despite aggressive sales efforts, collected premiums in the Life division have flatlined, showing virtually no growth year-over-year ($249.3M vs $245.5M in 25Q2).
⚖️ Verdict: 🟢
Bullish. Management is executing flawlessly on top-line growth and investment yield optimization. Raising annual EPS guidance by 8% mid-year is a strong signal of confidence, outweighing near-term expense and claims fluctuations.
Key Themes
Worksite Division Breakout
Accelerating. The Worksite division is becoming a critical growth engine. Worksite New Annualized Premium (NAP) surged 29% YoY to $23.3 million. This represents the 16th consecutive quarter of producing agent count growth. Life sales within Worksite saw massive adoption, driving the segment's profitability forward.
Investment Yield Expansion Continues
Stable/Accelerating. High macro interest rates remain CNO's strongest tailwind. General account net investment income rose 9% YoY to $411.9 million. With new money rates hovering above 6% for 13+ consecutive quarters, the portfolio book yield continues to climb, mechanically expanding operating margins.
Consumer Medicare Market Share Capture
Stable. The Consumer division delivered $104.4M in NAP, up from $101.9M a year ago. CNO continues to exploit a massive industry shift: consumers abandoning Medicare Advantage (MA) in favor of Medicare Supplement products. As an underwriter of Med Supp and merely a distributor of MA, CNO benefits economically from this rotation.
Policy Benefits Growth Outpacing Income
Reversing/Concerning. The flawlessly executed sales narrative masks a brewing issue in claims. In 26Q2, Insurance Policy Income grew 4.5% YoY, but Insurance Policy Benefits jumped 12.8% YoY ($742.5M vs $658.4M). Management previously flagged 'modestly adverse' Med Supp claims in Q1, and this spike suggests utilization pressures are lingering and currently offsetting some volume gains.
TechMod Initiative Drag
Stable. The three-year technology modernization project (TechMod) initiated in 2025 continues to weigh on the bottom line. Expenses related to TechMod hit $9.7M in Q2 (up from $3.2M in 25Q2), dragging down non-operating income. While necessary for long-term direct-to-consumer (D2C) efficiency, it limits free cash flow generation in the interim.
Life Insurance Stagnation
Decelerating. Despite records in annuities and health segments, the Life product line is struggling to find gear. Collected life premiums were essentially flat YoY ($249.3M vs $245.5M), while Life NAP was slightly down sequentially from Q4 highs. CNO needs to show that its recent pivot to digital lead generation can sustainably revitalize this segment.
Other KPIs
Accelerating. Up significantly from 11.2% in 25Q2 (excluding significant items). The company has successfully surpassed its 12% target waypoint, driven by strong core product margins and structural expense leverage from top-line growth.
Stable. The company remains committed to returning capital, executing $60.0 million in share repurchases (1.3 million shares at $46.57 average) and paying out $16.8 million in dividends during the quarter. The debt-to-capital ratio ex-AOCI remains healthy at 26.1%.
Accelerating. Rebounded nicely from $433.8 million in Q1 and up slightly from a tough comparable of $520.5 million in 25Q2. The middle-income demand for fixed indexed and fixed interest annuities remains a powerful driver of investable asset growth.
Guidance
Accelerating. Management explicitly raised full-year 2026 operating EPS guidance by 8% at the midpoint compared to prior expectations (which were originally set around $4.35). This implies a revised midpoint approaching $4.70, reflecting high confidence in H2 2026 core operations and investment yields.
Key Questions
Med Supp Morbidity and Rate Increases
Insurance policy benefits grew nearly 13% YoY in Q2, significantly outpacing premium growth. Is this driven entirely by the 'modestly adverse' Med Supp claims flagged in Q1, and are the 10-14% rate increases filed earlier this year sufficient to arrest this margin compression?
Life Segment Stagnation
Collected premiums in the Life segment were essentially flat year-over-year. Is this a result of macro headwinds impacting discretionary middle-market spending, or are we seeing a ceiling in the direct-to-consumer digital pivot?
FABN Market Appetite
In Q1, you noted the spread environment for funding agreement-backed notes (FABN) was unfavorable. Has this market opened back up in Q2 or Q3, and how is it impacting your unallocated net investment income expectations for the back half of the year?